Chlorthalidone Has Not Been Recalled
Chlorthalidone remains an FDA-approved medication that is actively prescribed and available in the United States. There is no evidence of any recall or withdrawal of this thiazide-like diuretic from the market 1.
Current Status and Prescribing Trends
Chlorthalidone continues to be manufactured, distributed, and prescribed for hypertension management. Recent prescription data from 2019-2024 shows an average of 543,402 chlorthalidone prescriptions dispensed monthly in the United States, though this represents only about 1/7th the volume of hydrochlorothiazide prescriptions 2. The medication remains listed in current clinical practice guidelines as a first-line antihypertensive agent 3, 4.
Why This Question May Arise
The confusion about chlorthalidone's availability may stem from several factors:
Declining prescription rates: Following the December 2022 Diuretic Comparison Project (DCP) report, chlorthalidone prescriptions showed a slowdown in growth, with monthly increases dropping from 3,602 to 864 prescriptions 2. This represents a change in prescribing patterns, not a recall.
Safety concerns: Chlorthalidone carries known risks of hypokalemia, hyponatremia, acute renal failure, chronic kidney disease progression, and hyperglycemia—all occurring more frequently than with hydrochlorothiazide 5. Severe cases of hypokalemic rhabdomyolysis have been reported, even with modest dose increases 6. These safety signals may create perception of restricted availability.
Guideline evolution: While the 2017 ACC/AHA guidelines recommended chlorthalidone as preferred over hydrochlorothiazide based on superior 24-hour blood pressure control 7, 3, more recent evidence from 2020 showed no significant cardiovascular benefit difference between the two agents (calibrated HR 1.00,95% CI 0.85-1.17) 5, 8, 9.
Clinical Implications
Chlorthalidone remains appropriate for specific clinical scenarios, particularly:
Resistant hypertension with advanced CKD: The CLICK trial demonstrated a 10.5 mmHg reduction in 24-hour systolic blood pressure in stage 4 CKD patients, with even greater benefit (13.9 mmHg reduction) in those with treatment-resistant hypertension 10, 11
When longer duration of action is desired: Chlorthalidone's prolonged half-life provides sustained blood pressure reduction 7
However, close monitoring is essential given the 2.72-fold increased risk of hypokalemia, 1.37-fold increased risk of acute renal failure, and 1.21-fold increased risk of type 2 diabetes compared to hydrochlorothiazide 5. Electrolyte monitoring should occur shortly after initiation and periodically thereafter 12, 1.
The medication is available in 25 mg and 50 mg tablets, with typical dosing of 12.5-25 mg daily for hypertension, up to a maximum of 50 mg daily 12, 1.